Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis

Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis

“…The included studies were published from 2015 to 2020 and contained extractable data on 514 patients enrolled from 2014 to 2016. Four studies were retrospective [10][11][12][13] and 16 were prospective [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] . Nine of the studies were conducted in India 10,12,14,16,18,20,22,25,29 , 2 in the USA 15,21 , 2 in Pakistan 24,28 , 2 in China 19,27 , 1 in France 17 , the Czech Republic 11 , Korea 13 , Iraq 26 , and 1 enrolled patients from multiple countries 23 .…”

“…A total of 19 studies reported extractable data on the SOF dose [10][11][12][13][14][16][17][18][19][20][21][22][23][24][25][26][27][28][29] and the other DAA included in the treatment regimen. In nine studies [10][11][12][13]16,19,[21][22][23] , the same treatment regimen was used for all study participants.…”

“…A sub-group analysis was not performed for the various other DAA used in the treatment regimens, due to the large variability of DAA used. Ribavirin was used in 6 studies 10,13,14,16,18,28 , simeprevir in 3 15,17,21 , ledipasvir in 8 17,[20][21][22][25][26][27]29 , daclatasvir in 9 10,11,14,[16][17][18][19][20][24][25][26][27][28][29] and velpatasvir in 2 studies 12,23 (Table 1).…”

“… 19 2016 Prospective China 33 52.8 72.7 GT-1a: 21, GT-2a: 73, GT-1b + 2a:6 DCV 200 mg daily 33 (100%) Mehta et al . 20 2016 Prospective India 38 49.5 68.4 GT-1a: 42, GT-1b: 58 LDV, DCV 400 mg daily, 400 mg AD 33 (87%) Sperl et al . 11 2015–2016 Retrospective Czech Republic 6 39 100 GT-3:100 DCV 200 mg daily 6 (100%) Surendra et al .…”

“…Four studies were retrospective 10 – 13 and 16 were prospective 14 – 29 . Nine of the studies were conducted in India 10 , 12 , 14 , 16 , 18 , 20 , 22 , 25 , 29 , 2 in the USA 15 , 21 , 2 in Pakistan 24 , 28 , 2 in China 19 , 27 , 1 in France 17 , the Czech Republic 11 , Korea 13 , Iraq 26 , and 1 enrolled patients from multiple countries 23 . All studies received more than five stars in the Newcastle–Ottawa Scale and no study was excluded due to quality concerns.…”